AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31779179
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D and calcium fortified yogurt (400 IU of vitamin D3 and 800 mg calcium daily for 3 months)
Trial: 31779179
Drug: Non-fortified yogurt
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-fortified yogurt (300 mg calcium, no vitamin D3)
Trial: 27670603
Drug: Amoxicillin group
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin group
Trial: 19349548
Drug: Dose-intensified regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-intensified regimen of vincristine, cyclophosphamide, doxorubicin (VDC), and dactinomycin alternating with ifosfamide and etoposide (IE) over 30 weeks
Trial: 17764540
Drug: Dabigatran etexilate
RxNorm normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dabigatran etexilate 220 mg once-daily
Trial: 17764540
Drug: Dabigatran etexilate
RxNorm normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dabigatran etexilate 150 mg once-daily
Trial: 17764540
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (Dabigatran 220 mg, Dabigatran 150 mg, Enoxaparin)
Trial: 15139393
Drug: Pork meat
RxNorm normalized name: Pork
DrugBank: Pork (DB10561)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pork meat diet (170 g pig meat/10 MJ per day, 106 +/- 13 microg Se/d)
Trial: 9919621
Drug: Nicotinic acid
RxNorm normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotinic acid supplementation at 0-100 mg/day for 14 weeks
Trial: 7750677
Drug: Mannitol group
RxNorm normalized name: Mannitol
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mannitol group (n = 20) treated by whole gut irrigation with a 5 L solution containing 40 g/L of mannitol
Trial: 3281488
Drug: C25 (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C25 (25 mg/kg chloroquine over 3 days)
Trial: 3281488
Drug: C50 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C50 (50 mg/kg chloroquine over 5 days)
Trial: 1363409
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of hydrocortisone succinate, 100 mg bolus at time 0 followed by 250 mg in 250 ml saline for 120 min
Trial: 1363409
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of saline, 250 ml
Trial: 408839
Drug: l-tryptophane 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-tryptophane 1 g
Trial: 408839
Drug: l-tryptophane 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-tryptophane 3 g
Trial: 27085364
Drug: Autologous PRP
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous PRP therapy combined with a rehabilitation programme
Trial: 21966999
Drug: Darbepoetin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darbepoetin (300 μg)
Trial: 19363974
Drug: Adper Prompt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adper Prompt L-Pop (ADP)
Trial: 14688150
Drug: Estrogen‐progestin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen‐progestin treatment (HRT)
Trial: 11451717
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g highly concentrated n‐3 fatty acids
Trial: 9540761
Drug: Meropenem (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meropenem (1 g every 8 h)
Trial: 9540761
Drug: Ceftazidime (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime (2 g every 8 h) and Amikacin (15 mg/kg/day)
Trial: 29406463
Drug: Lopinavir‐based antiretroviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir‐based antiretroviral therapy (ART)
Trial: 27422740
Drug: Vedolizumab (0.2,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vedolizumab (0.2, 0.5, 2.0, 6.0, or 10.0 mg/kg)
Trial: 23689561
Drug: Calcium co-ingestion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium co-ingestion (15 mg/kg body mass)
Trial: 23689561
Drug: Control meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control meal (3 mg/kg body mass)
Trial: 22275153
Drug: No rectal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No rectal distension (control)
Trial: 20487528
Drug: Intensive educational
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive educational intervention consisting of group sessions with standardised information about OAC therapy, lifestyle interactions, and INR monitoring.
Trial: 18779274
Drug: Milk intervention
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk intervention (3 servings/day, approximately 200 g per serving)
Trial: 6372925
Drug: Treatment-as-usual (including
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-as-usual (including antidepressant medication)
Trial: 24576532
Drug: paliperidone extended-release
RxNorm normalized name: Paliperidone Extended-Release Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: paliperidone extended-release (3-12 mg)
Trial: 24576532
Drug: paliperidone extended-release
RxNorm normalized name: Paliperidone Extended-Release Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: paliperidone extended-release
Trial: 20357160
Drug: Sugammadex (2,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex (2, 4, and 16 mg/kg)
Trial: 7774513
Drug: Enoxaparin 30
RxNorm normalized name: ENOXAPARIN 30MG/0.3ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 30 mg twice daily, initiated post-operatively
Trial: 7774513
Drug: Enoxaparin 40
RxNorm normalized name: ENOXAPARIN 40MG/0.4ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 40 mg once daily starting preoperatively
Trial: 2200994
Drug: Cefaclor (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefaclor (40 to 50 mg/kg/day for 10 days) in 3 divided doses (group 1)
Trial: 2200994
Drug: Cefatrizine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefatrizine (40 to 50 mg/kg/day for 10 days) in 3 divided doses (group 2)
Trial: 2200994
Drug: Cefatrizine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefatrizine (40 to 50 mg/kg/day for 10 days) in 2 divided doses (group 3)
Trial: 17389151
Drug: Telmisartan and
RxNorm normalized name: telmisartan and diuretics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan and hydrochlorothiazide combination therapy, dosage and duration not specified.
Trial: 11208684
Drug: Adjusted for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjusted for baseline and treatment differences
Trial: 6299620
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg of the met-enkephalin analogue, DAMME
Trial: 6299620
Drug: 16 mg
RxNorm normalized name: escin 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mg of the opiate antagonist, naloxone
Trial: 6299620
Drug: Insulin-induced hypoglycaemia
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin-induced hypoglycaemia (0.15 u/kg) or naloxone (25 mg)
Trial: 17405568
Drug: Resynchronization therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resynchronization therapy
Trial: 15618785
Drug: Esmolol bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol bolus of 1 mg/kg followed by a continuous infusion of 150 microg.kg.min
Trial: 12477060
Drug: Tazarotene gel
RxNorm normalized name: Tazarotene
DrugBank: Tazarotene (DB00799)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tazarotene gel 0.1% b.i.d. for eight consecutive weeks
Trial: 9174183
Drug: Liposomal amphotericin
RxNorm normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liposomal amphotericin B (AmBisome) at a dose of 2.8 to 3.0 mg/kg
Trial: 9174183
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B deoxycholate at a standard dose of 1.0 mg/kg
Trial: 3096782
Drug: Metoclopramide (MTC)
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoclopramide (MTC) administered orally in daily doses from 20 to 7.5 mg for 10 weeks
Trial: 12455427
Drug: 6-session cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-session cognitive-behavioral therapy (CBT) in conjunction with usual TMD treatment
Trial: 12455427
Drug: Usual conservative
RxNorm normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual conservative treatment by TMD specialist dentists
Trial: 10501817
Drug: Iloprost infusion
RxNorm normalized name: Iloprost
DrugBank: Iloprost (DB01088)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iloprost infusion (3 ng kg(‐1) min(‐1) for 5 h) for 1 day (short-term treatment)
Trial: 10501817
Drug: Iloprost infusion
RxNorm normalized name: Iloprost
DrugBank: Iloprost (DB01088)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iloprost infusion (3 ng kg(‐1) min(‐1) for 5 h) over a period of 28 days (long-term treatment)
Trial: 10501817
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion (for 5 h) for 1 day (control treatment)
Trial: 10501817
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion over a period of 28 days (placebo treatment)
Trial: 8931888
Drug: New sustained
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New sustained release formulation of diltiazem (120 mg)
Trial: 8931888
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of diltiazem (120 mg)
Trial: 30333359
Drug: Oral tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tranexamic acid 250 mg twice a day
Trial: 30333359
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid microinjections (4 mg/ml) monthly
Trial: 21344797
Drug: Cissus quadrangularis
RxNorm normalized name: Cissus quadrangularis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cissus quadrangularis L. (3 x 2 p.c. for 4 days and then 2 x 2 p.c. for 3 days)
Trial: 12147790
Drug: Angiotensin-converting enzyme
RxNorm normalized name: ACE - Angiotensin-converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor antagonists (ARB)
Trial: 12147790
Drug: Antihypertensive medication
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive medication (AHM) increase
Trial: 9504938
Drug: Bosentan 500
RxNorm normalized name: Bosentan
DrugBank: Bosentan (DB00559)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bosentan 500 mg once daily
Trial: 9504938
Drug: Bosentan 1000
RxNorm normalized name: Bosentan
DrugBank: Bosentan (DB00559)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bosentan 1000 mg twice daily
Trial: 1152314
Drug: Puppet therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Puppet therapy (puppet show designed to familiarize patients with hospital routines and procedures)
Trial: 28371025
Drug: Sildenafil (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (50 mg, taken 1 hour before sexual activity, adjustable to 100 or 25 mg)
Trial: 1685841
Drug: Hydrocolloid dressing
RxNorm normalized name: hydrocolloid dressing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocolloid dressing (Actiderm) plus triamcinolone acetonide (TAA) 0.1% cream applied every third day
Trial: 1685841
Drug: Clobetasol propionate
RxNorm normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Clobetasol propionate 0.05% cream applied twice daily for 4 weeks
Trial: 24731567
Drug: Intensive-dose atorvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive-dose atorvastatin therapy (IAT, 40mg/day)
Trial: 24731567
Drug: Standard-dose atorvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose atorvastatin therapy (SAT, 20mg/day)
Trial: 24731567
Drug: Low-dose atorvastatin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose atorvastatin therapy (LAT, 10mg/day)
Trial: 24731567
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment groups (IAT, SAT, LAT)
Trial: 19936872
Drug: SRP, chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRP, chlorhexidine gel 0.5%, three sessions of KTP laser irradiation
Trial: 19936872
Drug: SRP, chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRP, chlorhexidine gel 0.5%
Trial: 12601104
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg sumatriptan nasal spray
Trial: 10229408
Drug: Immediate release
RxNorm normalized name: Namenda, immediate release oral kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate release oxycodone-APAP
Trial: 8740103
Drug: Foscarnet 90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foscarnet 90 mg/kg b.i.d. 5 days for 3 weeks
Trial: 8740103
Drug: Foscarnet 90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foscarnet 90 mg/kg b.i.d. daily (7 days a week)
Trial: 1928165
Drug: Heparin-bonded PA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-bonded PA catheters made of polyvinylchloride or polyurethane
Trial: 1928165
Drug: Heparin-bonded PA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-bonded PA catheters
Trial: 6351455
Drug: Norfenefrin infusion
RxNorm normalized name: norfenefrine
DrugBank: Norfenefrine (DB13378)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norfenefrin infusion (2-4 mg/kg per minute)
Trial: 26861783
Drug: Empagliflozin administration
RxNorm normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Empagliflozin administration
Trial: 26861783
Drug: Chronic (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic (4 weeks) empagliflozin administration
Trial: 22458741
Drug: Telmisartan/Amlodipine (T/A)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan/Amlodipine (T/A) single-pill combination (SPC)
Trial: 17011678
Drug: Intradermal (ID)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal (ID) injection of 0.1 ml dose of inactivated split‐virion influenza vaccine
Trial: 17011678
Drug: Intramuscular (IM)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (IM) injection of 0.5 ml dose of inactivated split‐virion influenza vaccine
Trial: 15843666
Drug: Azithromycin 600
RxNorm normalized name: azithromycin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 600 mg weekly for one year
Trial: 7569455
Drug: 30 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 µg of estrogen and 300 µg of progestogen (Group 2)
Trial: 7569455
Drug: 35 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35 µg of estrogen and 500 µg of progestogen (Group 3)
Trial: 7569455
Drug: 30 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 µg of levonorgestrel (Group 4)
Trial: 2169779
Drug: Granisetron 40
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Granisetron 40 micrograms/kg (additional doses for breakthrough nausea)
Trial: 6986949
Drug: Captopril, 100
RxNorm normalized name: Captopril, 100 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril, 100 mg orally
Trial: 27735931
Drug: Inhaled hydrofluoalkane-beclomethasone
RxNorm normalized name: beclomethasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled hydrofluoalkane-beclomethasone dipropionate (QVAR) 100 μg per dose, twice daily via Aerochamber with face mask
Trial: 23949258
Drug: EHK02‐01 cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EHK02‐01 cream applied twice daily for 28 days
Trial: 23949258
Drug: Control cream
RxNorm normalized name: BENZOYL PEROXIDE 3 mg in 60 mL TOPICAL LIQUID [Acnecare Dermacontrol Cream]
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control cream applied twice daily for 28 days
Trial: 22575040
Drug: L-alanylglutamine (AlaGln)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-alanylglutamine (AlaGln) at 89 mg/kg
Trial: 22575040
Drug: L-glutamine (L-Gln)
DrugBank: L-Glutamine (DB00130)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-glutamine (L-Gln) at 60 mg/kg
Trial: 22575040
Drug: Enzymatically hydrolyzed
RxNorm normalized name: hydrolyzed sericin (enzymatic; 2500 MW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzymatically hydrolyzed wheat protein (HWP) at 200 mg/kg
Trial: 19412108
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion (0.03‐0.1 microg kg min)
Trial: 19412108
Drug: Fentanyl (1‐3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (1‐3 microg kg) and midazolam (0.05‐0.1 mg kg)
Trial: 12355937
Drug: Concurrent chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiotherapy for localized disease of both small and non-small cell lung cancers
Trial: 12355937
Drug: Adjuvant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant treatment methods for resected patients
Trial: 17846310
Drug: G-CSF (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF (10 microg/kg/d)
Trial: 1097925
Drug: Propranolol (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (160 to 320 mg per day for six and 12 weeks)
Trial: 31326727
Drug: liraglutide/metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: liraglutide/metformin
Trial: 23155151
Drug: boceprevir (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: boceprevir (800 mg, 3 times daily) for 6 days followed by atazanavir (300 mg once daily) with ritonavir (100 mg) on days 10-31, plus concomitant boceprevir on days 25-31
Trial: 23155151
Drug: boceprevir (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: boceprevir (800 mg, 3 times daily) for 6 days followed by lopinavir (400 mg twice daily) with ritonavir (100 mg) on days 10-31, plus concomitant boceprevir on days 25-31
Trial: 23155151
Drug: boceprevir (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: boceprevir (800 mg, 3 times daily) for 6 days followed by darunavir (600 mg twice daily) with ritonavir (100 mg) on days 10-31, plus concomitant boceprevir on days 25-31
Trial: 23155151
Drug: boceprevir (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: boceprevir (800 mg, 3 times daily)
Trial: 19672236
Drug: Acatinol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acatinol (10 mg daily)
Trial: 19672236
Drug: Piracetam (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piracetam (1200 mg daily)
Trial: 16968405
Drug: Anti-IL-12 monoclonal
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-IL-12 monoclonal antibody
Trial: 16281467
Drug: Salk Polio
RxNorm normalized name: poliovirus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salk Polio Vaccine
Trial: 8280654
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Tamoxifen and Megestrol acetate
Trial: 2879457
Drug: Calcium entry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium entry blocker (nitrendipine)
Trial: 2879457
Drug: Beta adrenoreceptor
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta adrenoreceptor blocker (oxprenolol)
Trial: 31829907
Drug: Ganetespib 150
RxNorm normalized name: Ganetespib
DrugBank: Ganetespib (DB12047)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganetespib 150 mg/m2 on days 1 and 15 with docetaxel 75 mg/m2 on day 1 of a 21-day cycle
Trial: 29936130
Drug: Noninvasive image-guided
RxNorm normalized name: triclosan
DrugBank: Triclosan (DB08604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Noninvasive image-guided breast brachytherapy (NIBB) with a total dose of 28.5 Gy in five daily fractions.
Trial: 23139021
Drug: Guided Internet-delivered
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided Internet-delivered cognitive behavioural therapy for 8 weeks
Trial: 20477925
Drug: Acyclovir (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyclovir (400 mg five times a day for 1 week)
Trial: 18565240
Drug: Subcutaneous epoetin
RxNorm normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous epoetin beta (6000 IU weekly for 2 weeks)
Trial: 18565240
Drug: Subcutaneous darbepoetin
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous darbepoetin alfa (30 mug weekly for 2 weeks)
Trial: 16648085
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment based on acupuncture diagnosis